Skip to content

Clinical trials

Parkinson Disease trials in China with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Parkinson Disease Phase: Not applicable Country / region: China Clear all

116 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20051
20091
20113
20162
20174
20183
20196
202010
20219
202211
202316
202418
202516
202616

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status35
Completed33
Recruiting29
Not yet recruiting8
Enrolling by invitation5
Withdrawn4
Terminated1
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Ruijin Hospital14
Anhui Medical University8
The First Affiliated Hospital with Nanjing Medical University8
Beijing Tiantan Hospital4
Jiangsu Province Nanjing Brain Hospital4
Tsinghua University4
Beijing Pins Medical Co., Ltd3
Chinese PLA General Hospital3
Ke Dong, MD3
The Hong Kong Polytechnic University3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Parkinson Disease116
Sleep Wake Disorders6
Parkinsonian Disorders5
Cognitive Dysfunction4
Gait Disorders, Neurologic4
Movement Disorders3
Alzheimer Disease2
Dyskinesias2
Lethargy2
Sleep Initiation and Maintenance Disorders2

Trials

Showing 1 to 25 of 116. Each trial links to its page on Pharma Observatory.

16 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.